Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.81, $0.16 better than the analyst estimate of $0.65. Revenue for the quarter came in at $186.5 million versus the consensus estimate of $179.29 million.

GUIDANCE:

Repligen sees FY2022 EPS of $3.21-$3.30, versus the consensus of $3.15. Repligen sees FY2022 revenue of $800-830 million, versus the consensus of $801.46 million.

For earnings history and earnings-related data on Repligen (RGEN) click here.